Skip to content
Review Open access

Perioperative treatment for resectable non-small cell lung cancer harboring EGFR exon 20 insertion mutations: a narrative review from advanced-stage evidence to whole-course precision management

Sep 2026 · Translational Lung Cancer Research · Vol 15, pp. 325-325 · 0 citations · 60 references
Medicine

TL;DR

Advanced-stage evidence supports perioperative investigation but cannot establish benefit in resectable disease, and progress requires accurate variant-level testing and randomized trials defining pathological response, surgical feasibility, toxicity, central nervous system (CNS) control, DFS, and OS.

Abstract

Background and Objective Epidermal growth factor receptor exon 20 insertion mutations (EGFR ex20ins) define a rare, structurally heterogeneous subtype of non-small cell lung cancer (NSCLC) that is relatively insensitive to conventional EGFR tyrosine kinase inhibitors. Although amivantamab, sunvozertinib, zipalertinib, furmonertinib, and other EGFR ex20ins-directed agents have expanded treatment options in advanced disease, their role in resectable NSCLC remains undefined. This narrative review summarizes the biological and clinical characteristics of EGFR ex20ins and critically evaluates advanced-stage evidence and emerging perioperative strategies. Methods PubMed, Web of Science, Scopus, Google Scholar, major preprint servers, oncology conference proceedings, trial registries, and regulatory sources were searched initially on June 3, 2026, with a targeted update on August 24, 2026. Peer-reviewed primary studies were prioritized; regulatory records, trial registries, conference abstracts, and preprints were included when they provided relevant emerging evidence. English- and Chinese-language publications were considered. Key Content and Findings EGFR ex20ins comprise heterogeneous insertion, duplication, and deletion-insertion variants with distinct conformational effects and drug sensitivity. Advanced-stage studies have established clinically relevant activity for EGFR/c-MET bispecific antibodies and novel EGFR ex20ins-directed tyrosine kinase inhibitors (TKIs), including randomized phase III progression-free survival (PFS) benefits for selected regimens. Perioperative studies are evaluating sunvozertinib, zipalertinib, furmonertinib, and amivantamab; however, evidence remains limited to ongoing trials, case reports, small series, and immature conference data, without mature randomized event-free survival (EFS), disease-free survival (DFS), or overall survival (OS) results. Conclusions Advanced-stage evidence supports perioperative investigation but cannot establish benefit in resectable disease. Progress requires accurate variant-level testing and randomized trials defining pathological response, surgical feasibility, toxicity, central nervous system (CNS) control, DFS, and OS.

Read PDF

Similar papers

Review Open access Nov 2026

Expert consensus on the diagnosis and treatment of EGFR gene mutation non-small cell lung cancer

Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...

R. Meng, Chun-Wei Xu, Wen-Xian Wang et al. · 0 citations
Review Open access Nov 2026

Clinical outcomes of targeted treatment strategies for primary non-small cell lung cancer with MET alterations: a systematic review and meta-analysis

Primary non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor ( MET ) gene alterations, including exon 14 skipping mutations and amplification, represents a distinct molecular subtype with unique therapeutic challenges. While multiple tyrosine kinase inhibitor (TKI) strategies have be...

Z. Meng, H. Deng, Jing-Wen Han et al. · 0 citations
Review Open access Oct 2026

A Narrative Review of the Cases of Co-altered EGFR and ALK in Non-small Cell Lung Cancers: An Attempt to Break the Therapeutic Dilemma

Molecular profiling is essential in advanced non-small cell lung cancer (NSCLC) to identify actionable genetic alterations and guide targeted therapies. While epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are historically considered mutually exclusive alterations,...

Amitabh Kumar Upadhyay, Manoj Kumar, A. Prakash et al. · 0 citations
Review Open access Sep 2026

AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems.

ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed,...

Fu-Xiang Wang, Hong-Chi Jiang, Yan Chen et al. · 0 citations
Open access Nov 2026

Case Report: Long-term survival of a patient with lung adenocarcinoma harboring EGFR 19del/T790M/C797S and KIF26B-NTRK1 rearrangement

Epidermal growth factor receptor (EGFR) gene mutation stands as one of the most prevalent driver genetic alterations in non-small cell lung cancer (NSCLC). While targeted therapies against EGFR have substantially enhanced patient prognosis, acquired resistance remains a core challenge that limits therapeutic efficacy....

Zhuo-Ying Li, Rui Liu, Jian-Ping Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.